STEM-LIKE CELLS IN BONE SARCOMAS

• US 20090239217A1
• Filed: 03/24/2008
• Published: 09/24/2009
• Est. Priority Date: 10/08/2007
• Status: Abandoned Application

• Current Assignee: University of Florida Research Foundation, Incorporated (State University System of Florida)
• Original Assignee: University of Florida Research Foundation, Incorporated (State University System of Florida)
• Inventors: STEINDLER, Dennis, GIBBS, Charles Parker JR.
• Application Number:
  US12/054,139
• Publication Number:
  US 20090239217A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C12N 2503/02 Drug screening
• CPC Class Codes: C12N 5/0695 Stem cells; Progenitor cells; Precursor cells

Abstract

Isolation and purification of stem cells from within a bulk sarcoma tumor. These cells express the marker genes of pluripotent embryonic stem cells, Stat 3, Oct 3/4, and Nanog. A subset of these cells show the surface marker of mesenchymal stem cells Stro-1, as well as express attributes of mesodermal, ectodermal, and endodermal differentiation. The isolation, purification and characterization of these stem cells now provides the ideal target for the development of highly effective therapies against tumors.

Claims

1. A method comprising the steps of providing a sample comprising a plurality of cells from a subject having osteosarcoma;

introducing into the cells a nucleic acid comprising an Oct-4 promoter operably linked to a reporter gene;

culturing the cells under conditions in which the reporter gene is expressed in the presence of at least one protein that activates the Oct-4 promoter;

analyzing the cells for expression of the reporter gene; and

correlating expression of the reporter gene with the presence of at least one osteosarcoma cancer stem cell.

2. The method of claim 1, wherein the at least one protein that activates the Oct-4 promoter is Oct-4.

3. The method of claim 1, wherein the at least one osteosarcoma cancer stem cell expresses Oct 3/4 or Nanog.

4. The method of claim 1, wherein the at least one osteosarcoma cancer stem cell comprises at least one stem cell marker selected from the group consisting of:

activated Stat-3 CXCR4, CD 133, SCA-1, Tra-1-60, CD 44, CD 73, CD 90, CD 105 and Stro-1.

5. The method of claim 1, wherein the plurality of cells is isolated from a sarcoma.

6. The method of claim 5, wherein the sarcoma is osteosarcoma or chondrosarcoma.

7. The method of claim 5, wherein the sarcoma is isolated from a mammal.

8. A method of inhibiting tumorigenesis in a population of cells, the method comprising contacting the population of cells with at least one agent that blocks Oct-4 promoter activity in the cells, wherein contacting the cells with the at least one agent induces at least one cell in the population of cells to differentiate.

9. The method of claim 8, wherein the at least one agent is a bone morphogenetic protein.

10. The method of claim 9, wherein the bone morphogenetic protein is selected from the group consisting of:

BMP 4/7, BMP 2, BMP 4, and BMP 7.

11. The method of claim 8, further comprising isolating the at least one osteosarcoma cancer stem cell.

12. A method of identifying candidate therapeutic compounds for osteosarcoma comprising:

culturing osteosarcoma cancer stem cells expressing at least one marker selected from;

Oct 3/4, Nanog, activated Stat-3, CXCR4, CD 133, SCA-1, Tra-1-60, CD 44, CD 73, CD 90, CD 105 and Stro-1 with at least one candidate therapeutic agent;

analyzing the osteosarcoma cancer stem cells for inhibition of at least one characteristic selected from the group consisting of;

growth and migration to a tumor; and

correlating inhibition of the at least one characteristic with the candidate therapeutic agent.

13. The method of claim 12, wherein a candidate therapeutic agent comprises organic molecules, inorganic molecules, vaccines, antibodies, nucleic acid molecules, proteins, peptides and vectors expressing nucleic acid molecules.